Patient Characteristics, Treatment, and Outcome After Relapse
| Patient . | Site . | Immunotype . | Karyotype . | Treatment . | Response . | CR2 Duration (mo) . | Current Status . | Clonal Marker . |
|---|---|---|---|---|---|---|---|---|
| 1 | Marrow + testes | Common | Hypodiploid 45XY | Chemo + XRT | CR2 | 27 | CCR2 | IgH FR2 (260 bp) |
| 2 | Marrow | Common | NK | Chemo | CR2 | 26 | Relapse death | Failed* |
| 3 | Marrow | Pre-B | NK | Chemo | CR2 | 134 | CCR2 | IgH FR3 (125 bp) |
| 4 | Marrow | Common | 46XY,del 14q,t(12;17) | Chemo | CR2 | 18 | CCR2 | IgH FR3 (120 bp) |
| 5 | Pelvic | Common (APAAP) | NK | Chemo + autograft | CR2 | 106 | CCR2 | Failed* |
| 6 | Marrow | Common | Normal | Chemo | CR2 | 113 | CCR2 | IgH FR3 (130 bp) |
| 7 | Marrow | Pre-B | Tetraploid 92-94, del 4q, t(9;12)del10q | Chemo + autograft | CR2 | 26 | Relapse death | IgH FR2 (250 bp) |
| 8 | Marrow | Common | Normal | Chemo | CR2 | 94 | CCR2 | IgH FR3 |
| 9 | Marrow | Common | Normal | Chemo | CR2 | 96 | CCR2 | TCRδ (vδ2-Dδ-Dδ3 240 bp) |
| 10 | Marrow | Common | NK | Chemo + allograft | CR2 | 36 | CCR2 | IgH FR3 (120 bp) |
| 11 | Marrow | Common | NK | Chemo + allograft | CR2 | 12 | Relapse death | IgH FR2 (260 bp) |
| 12 | Marrow | Common | 46XY t(9:22)(q34;q11) | Chemo | CR2 | 27 | Relapse death | IgH FR3 (120 bp) |
| Median (range) | 30 (12-134) | |||||||
| Patient . | Site . | Immunotype . | Karyotype . | Treatment . | Response . | CR2 Duration (mo) . | Current Status . | Clonal Marker . |
|---|---|---|---|---|---|---|---|---|
| 1 | Marrow + testes | Common | Hypodiploid 45XY | Chemo + XRT | CR2 | 27 | CCR2 | IgH FR2 (260 bp) |
| 2 | Marrow | Common | NK | Chemo | CR2 | 26 | Relapse death | Failed* |
| 3 | Marrow | Pre-B | NK | Chemo | CR2 | 134 | CCR2 | IgH FR3 (125 bp) |
| 4 | Marrow | Common | 46XY,del 14q,t(12;17) | Chemo | CR2 | 18 | CCR2 | IgH FR3 (120 bp) |
| 5 | Pelvic | Common (APAAP) | NK | Chemo + autograft | CR2 | 106 | CCR2 | Failed* |
| 6 | Marrow | Common | Normal | Chemo | CR2 | 113 | CCR2 | IgH FR3 (130 bp) |
| 7 | Marrow | Pre-B | Tetraploid 92-94, del 4q, t(9;12)del10q | Chemo + autograft | CR2 | 26 | Relapse death | IgH FR2 (250 bp) |
| 8 | Marrow | Common | Normal | Chemo | CR2 | 94 | CCR2 | IgH FR3 |
| 9 | Marrow | Common | Normal | Chemo | CR2 | 96 | CCR2 | TCRδ (vδ2-Dδ-Dδ3 240 bp) |
| 10 | Marrow | Common | NK | Chemo + allograft | CR2 | 36 | CCR2 | IgH FR3 (120 bp) |
| 11 | Marrow | Common | NK | Chemo + allograft | CR2 | 12 | Relapse death | IgH FR2 (260 bp) |
| 12 | Marrow | Common | 46XY t(9:22)(q34;q11) | Chemo | CR2 | 27 | Relapse death | IgH FR3 (120 bp) |
| Median (range) | 30 (12-134) | |||||||
Patients 4 and 8 have been reported previously.5 6
Abbreviations: NK, not known (not performed or failed); CR, complete remission; IgH, immunoglobulin heavy chain gene rearrangement; FR2 and 3, framework 2 and 3; TCR, T-cell receptor rearrangement; CCR, continuing complete remission.
Failed DNA extraction.